I was just speaking with a very good friend of mine about what they thought of the likelihood of IBM licensing Akida and grok said this "
Yes, the activity strongly suggests **IBM is already actively experimenting with and integrating BrainChip's Akida neuromorphic technology** into their ecosystem (particularly via IBM Spectrum Symphony for workload orchestration), which makes a near-term licensing deal or deeper commercial collaboration feel quite plausible — perhaps within the next 6–18 months — though nothing official has been announced yet.
Here's why it looks promising based on recent developments (as of March 2026):
- **Kevin D. Johnson's hands-on demos and enthusiasm** — As an IBM Field CTO / Principal HPC Cloud Technical Specialist focused on Symphony, GPFS, LSF, AI/HPC workloads (including quantum and neuromorphic), he's publicly posted multiple detailed prototypes and blogs on IBM's community site. Examples include:
- Four-tier heterogeneous compute setups where Akida handles ultra-low-power inference (e.g., classifying market ticks in microseconds on milliwatts), retrained via quantum/Granite models, orchestrated by Symphony.
- Edge targeting systems built in five days using Akida at the sensor layer + Symphony orchestration + Palantir Foundry.
- Fun tests like running Doom on Akida ("fast and furious").
- Descriptions of closed-loop architectures with Akida triggering retraining.
These aren't casual mentions; they're technical deep-dives showing real integration testing, bug-fixing, and performance wins. He calls BrainChip "a case in point" for why he keeps working with their platform. This level of internal advocacy from a senior technical leader often precedes formal partnerships.
- **No official IBM-BrainChip partnership announced** — Searches across news, BrainChip's investor site, IBM pages, and broader web/X show zero press releases or statements about licensing, co-development, or reselling Akida. BrainChip's recent partnerships are with others (e.g., Klepsydra for heterogeneous runtimes, Neuromorphyx for defense/edge devices). IBM still highlights its own legacy neuromorphic work (TrueNorth, NorthPole) as research-focused, while Akida is positioned as commercially deployed and efficient for edge.
- **But the pattern fits IBM's strategy** — IBM often collaborates with or integrates third-party specialized hardware (e.g., via Symphony for hybrid HPC/AI/quantum workloads) rather than building everything in-house. Neuromorphic fills a gap for ultra-low-power, event-based edge inference that complements their classical HPC, Granite LLMs, and quantum efforts. Kevin's posts frame Akida as seamlessly fitting into Symphony-orchestrated pipelines.
- **Investor/community buzz** — On X and forums (e.g., hotcrapper, Reddit's r/BrainChipHoldings), people interpret Kevin's posts as strong signals of impending tie-up ("IBM must/will be using Akida," "perfect match"). This is typical $BRN hype, but it aligns with the technical evidence.
In short: It's not just idle curiosity — it's sustained, production-like testing by a key IBM figure. That often leads to licensing (BrainChip's business model includes IP licensing for integration into larger systems) or partnership. "Near future" could mean months if internal pilots succeed, but big tech moves slowly on formal deals. Watch for announcements from IBM Think, BrainChip investor updates, or more from Kevin — if he keeps posting wins without disclaimers, odds look good. No guarantees, but the tea leaves are positive.